首页> 外文期刊>Biologicals: Journal of the International Association of Biological Standardization >Comparability studies of hemin from two different origins porcine and bovine in the production of Haemophilus influenzae type b (Hib) polysaccharide
【24h】

Comparability studies of hemin from two different origins porcine and bovine in the production of Haemophilus influenzae type b (Hib) polysaccharide

机译:两种不同源猪和牛血红素的可比性研究在嗜血杆菌型B(HIB)多糖的生产中

获取原文
获取原文并翻译 | 示例
           

摘要

Hemin is one of the critical components of medium required for growth of Haemophilus influenzae type b (Hib) organisms. It is important to have different sources of critical components to ensure continuous supply for commercial production. Regulatory bodies also recommend having multiple sources for critical components. Hemin is produced from animal blood and the main sources are porcine and bovine origin. The approved Hib vaccine of SIIPL used for immunization is produced using hemin obtained from porcine origin. The present work focuses on the comparison of the growth of organisms on a large scale using hemin from bovine or porcine origin. Purified polysaccharide obtained using bovine source is tested with respect to the set WHO specifications as recommended by regulatory bodies and compared with commercial lots of PRP obtained from using hemin of porcine source. Identical product profile and quality attributes were obtained for PRP produced using bovine hemin and the regular commercial product suggests that there is no change in the product. Hemin from bovine source can be used as a replacement for hemin from porcine source in the fermentation medium for country specific requirement of Hib conjugate vaccine as long as it meets the guidelines on TSE/BSE risk.
机译:血红素是b型流感嗜血杆菌(Hib)生长所需培养基的关键成分之一。重要的是要有不同的关键部件来源,以确保商业生产的持续供应。监管机构还建议为关键组件提供多种来源。血红素由动物血液产生,主要来源于猪和牛。经批准用于免疫的SIIPL Hib疫苗是使用从猪源获得的血红素生产的。目前的工作集中在使用来自牛或猪的血红素大规模比较生物体的生长。根据监管机构推荐的WHO规范,对使用牛源获得的纯化多糖进行测试,并与使用猪源血红素获得的商业批次PRP进行比较。使用牛血红素生产的PRP获得了相同的产品特征和质量属性,常规商业产品表明该产品没有变化。牛源血红素可作为发酵培养基中猪源血红素的替代品,以满足Hib结合疫苗的国家特定要求,前提是其符合TSE/BSE风险指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号